후원로펌 뉴스레터

본문 바로가기

HOME > 후원로펌 현황 > 후원로펌 뉴스레터

후원로펌 현황

[법무법인 광장] Lee&Ko Successfully Challenges 13-Year Old System of Automatic Price Reduction of Original Drug to 53.55%

페이지 정보

작성일19-04-03 21:23

본문


상단 이미지

Lee&Ko Successfully Challenges 13-Year Old System of Automatic Reduction of Original Drug Price to 53.55%

The Seoul Administrative Court and the Seoul High Court issued orders suspending the automatic reduction of the price of the original drug “A” upon generic entry claiming patent non-infringement and the automatic reduction of the price of the original drug “B” upon generic entry claiming patent invalidity, respectively.  The automatic price reduction of the original drug B has been continuously suspended since the Administrative Commission’s suspension order issued in April 2018.

Original Drug Price Reduction Upon Generic Entry
Under the Korean National Health Insurance Act and related rules and regulations, the original drug price is automatically reduced to 53.55% when a generic product is approved and its price is registered, even during the term of a valid patent covering the original drug.  This price reduction scheme was first introduced in 2006 and has been in effect for 13 years to date.  Once reduced, the original drug price may only be recovered upon the Supreme Court’s final decision confirming patent infringement by the generic company (or a decision having an equivalent effect).

As a result, many innovator drug companies had to see their prices drop to near 50% upon generic entry.  Normally, innovator drug companies suffer huge losses of revenue due to the price reduction, and their loss of revenue attributable to market share loss would be small in comparison.

Against this backdrop, Lee&Ko presented an effective argument against the long-standing price reduction scheme and persuaded the courts to suspend the original drug price reduction following generic entry claiming invalidity or non-infringement.

March 15, 2019 Suspension Order Related To Negative Scope Confirmation Action – Generic Version of Original Drug “A” Claiming Non-Infringement
A generic manufacturer entered the market claiming non-infringement by filing a negative scope confirmation action (a declaratory judgment action in which the petitioner seeks a ruling that its specified product does not fall within the scope of the patent-at-issue).  After the generic product’s price was listed, the Ministry of Health and Welfare (“MOHW”) issued a notification that the price of the original drug “A” would be reduced.  Lee&Ko successfully persuaded the court to issue a suspension order by explaining how the scope confirmation action can be irrelevant to the actual generic product and the importance of strong patent protection.
March 18, 2019 Suspension Order Related To Invalidation Action – Generic Version of Original Drug “B” Claiming Invalidity
A generic manufacturer entered the market conceding infringement but claiming invalidity by filing an invalidation action.  After the generic product’s price was listed, MOHW issued a notification that the price of the original drug “B” would be reduced.  Lee&Ko obtained successive suspension orders by the Seoul Administrative Court and the Seoul High Court, by thoroughly explaining the unreasonableness of the automatic price reduction implemented without due consideration of patent infringement or validity issues.
Prevented Huge Losses of Revenue for Original Drug Manufacturer – Significant Impact on the Korean Pharmaceutical Industry Expected
Lee&Ko was able to prevent huge losses of revenue for the original drug manufacturer by achieving repeated success in protecting the original drug price by obtaining suspension orders against administrative dispositions automatically reducing the original drug price triggered by unlawful acts of generic manufacturers despite pending patent disputes.

Lee&Ko’s repeated success in suspending original drug price reduction has shed pertinent light on the problems entailed with the current drug price reduction scheme related to generic entry which has been in effect for more than 13 years and therefore is expected to have a significant impact on the pharmaceutical industry.  

─ CONTACT ─
Keum Nang PARK
Keum Nang PARK
T:82.2.2191.3036
E:keumnang.park
@leeko.com
profile>
Jung Hyun UHM
Jung Hyun UHM
T:+82.6386.6256
E:junghyun.uhm
@leeko.com
Profile>
Eunkyoung LYU
Eunkyoung LYU
T:+82.2191.3206
E:eunkyoung.lyu
@leeko.com
Profile>
For more information pertaining to this newsletter, please contact the attorneys identified on the right.
The Lee&Ko Legal Newsletter is provided for general information purposes only and should not be considered as the considered as the rendering of legal advice for any specific matter. If you no longer wish to receive our newsletter service, please click here or reply to this email stating UNSUBSCRIBE in the subject line. The contects and opinions expressed in the Lee&Ko Legal Newsletter are protected by law against any unauthorized use.
후원로펌 뉴스레터 목록
번호 제목 날짜
2508 [법무법인(유) 율촌] 금융회사등의 해외진출에 관한 규정의 주요 개정 사항 2024-02-23
2507 [법무법인(유) 율촌] 프랑스 정부, 전기차 구매보조금 지급 정책 개편 - 생산에 수반되는 탄소발자국 반영 2024-02-23
2506 [법무법인(유) 율촌] 율촌 입법 위클리 2024-06호 첨부파일 2024-02-23
2505 [법무법인(유) 화우] 가상융합산업 진흥법(메타버스 산업 진흥을 위한 법률) 제정 2024-02-23
2504 [법무법인(유) 화우] 개인정보위, 2024년 조사업무 추진방향 발표 2024-02-23
2503 [법무법인(유) 화우] 저성과자 해고의 정당성 판단 2024-02-23
2502 [법무법인(유) 화우] 문체부, 확률형 아이템 확률 정보공개 관련 해설서 발표 2024-02-23
2501 [법무법인(유) 화우] EU 이사회, 강제노동 제품 금지 관련 법안 입장 확정 2024-02-23
2500 [법무법인(유) 화우] 대주주적격성유지요건 충족명령 미이행에 따른 주식처분명령 취소 판결(서울행정법원) 2024-02-23
2499 [법무법인(유한) 태평양] 식약처, 2024년 주요 업무 추진계획 발표 – 「식의약 안심이 일상이 되는 세상」 2024-02-22
2498 [법무법인(유) 광장] PIPC Announces Policy Direction for the Protection of Online Behavioral Data Used in Targeted Advertising 2024-02-22
2497 [법무법인(유한) 대륙아주] Weekly_Legislative_Report_Week_of_February_12_to_February_16_2024 2024-02-22
2496 [법무법인(유한) 바른] 뉴스레터 - 제129호(2024.2) 2024-02-21
2495 [법무법인(유) 광장] 국토계획법 개정안 공포_융복합 도시공간 조성을 위한 제도 개선 2024-02-21
2494 [법무법인(유한) 대륙아주] AI 이슈리포트 - 유럽연합, AI 규제법안에 대하여 전격 합의 2024-02-21
게시물 검색

사단법인 인하우스카운슬포럼 In-House Counsel Forum

주소 : 서울시 강남구 테헤란로 625, 17층 | 고유번호 : 107-82-14795

E-mail : reps@ihcf.co.kr

Copyright(C) IHCF KOREA. ALL RIGHTS RESERVED.

모바일 버전으로 보기